Puma Biotechnology Inc.'s (NYSE: PBYI) breast cancer treatment neratinib may be too toxic to gain regulatory approval. The stock price plunged $10.30 to close at $40.10.
Puma Biotechnology's neratinib may be too toxic
November 14, 2016 at 17:30 PM EST
